# A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro

Source: https://onco.cc/trials/nct06218888/  
OnCo record `nct06218888` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab, fruquintinib and tucidinostat (chidamide) in colorectal cancer, run by Fujian Cancer Hospital, not yet recruiting.

## Summary

A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases is a phase 2, interventional study registered as NCT06218888 by Fujian Cancer Hospital, with a registry enrolment figure of 17 participants, started 2024-06-01 and due to reach its primary completion in 2025-12-01. Interventions recorded: Tislelizumab; Fruquintinib; Chidamide. Conditions listed: Colo-rectal Cancer. Primary outcome: Objective Response Rate（ORR）. Colorectal eligibility wording from the registry: "* Subjects with histologically and/or cytologically confirmed locally advanced unresectable or metastatic colorectal adenocarcinoma with liver metastasis (excluding adenosquamous carcinoma mixed with other pathological types)". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06218888
- Phase: 2
- Setting: A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
- Sponsor: Fujian Cancer Hospital
- Enrolled: 17

## Sources

- ClinicalTrials.gov NCT06218888: https://clinicaltrials.gov/study/NCT06218888

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06218888.json